Lumira Ventures | Activity | F4

Introducing F4 Champions, a new accelerator for founders at the earliest stage.F4 Champions for early-stage foundersEnrollment closesAugust 2Learn more

Team Portfolio Raise Champions Essays

F4/Lumira Ventures/Activity

Lumira Ventures Activity

Every public signal F4 has attached to this firm, with sources and cross-entity links.

Types

Time range

Milestone

Portfolio company Congruence Therapeutics announced a $39.5M financing to advance its portfolio of small-molecule correctors into the clinic.

Congruence Therapeutics

Congruence Therapeutics Lumira Ventures

lumiraventures.com

Added recently

Milestone

Portfolio company Endogenex closed a $50M Series C extension to fund a pivotal clinical study and its path to FDA approval.

Endogenex

Endogenex Lumira Ventures

lumiraventures.com

Added recently

Investment

Portfolio company COUR Pharmaceuticals announced the closing of a $50M Series B financing.

COUR Pharmaceuticals

COUR Pharmaceuticals Lumira Ventures

lumiraventures.com

Added recently

Press

Portfolio company Contraline's CEO Kevin Eisenfrats was interviewed on the future of male contraception.

Contraline CEO Kevin Eisenfrats on the Future of Male Contraception

Lumira Ventures

lumiraventures.com

Added recently

Investment

New Fund V investment in Contraline's $92.5M Series B, co-led by BVF Partners and RA Capital Management, to advance the NES/T male contraceptive gel into late-stage development.

Contraline

Contraline Lumira Ventures

lumiraventures.com

Added recently

News

Won the CVCA's 2026 VC Global Dealmaker Award for its HistoSonics investment.

2026 CVCA VC Global Dealmaker Award

Lumira Ventures

central.cvca.ca

Added recently

Investment

Cancer Breakthrough Fund participated in Altis Labs' $25M Series A to scale AI endpoints for oncology clinical trials.

Altis Labs

Altis Labs Lumira Ventures

lumiraventures.comSEP 17, 2026

SEP 17, 2026

Investment

Cancer Breakthrough Fund invested in Sound Blade Medical, co-led by Amzak Health and Lumira, to advance handheld histotripsy therapy for cancer.

Sound Blade Medical

Sound Blade Medical Lumira Ventures

lumiraventures.comJUL 27, 2026

JUL 27, 2026

Milestone

Portfolio company HistoSonics closed a new financing round with Reed Jobs and Yosemite, valuing the company at $3.75B.

HistoSonics

HistoSonics Lumira Ventures

lumiraventures.comJUN 22, 2026

JUN 22, 2026

New Fund

Announced an oversubscribed first close of the Cancer Breakthrough Fund with the Terry Fox Foundation and Canadian Cancer Society, exceeding its $30M initial target and targeting a $50M hard cap.

Cancer Breakthrough Fund first close

Lumira Ventures

lumiraventures.comMAY 5, 2026

MAY 5, 2026

Investment

Fund V's first investment: participated in Nervonik's oversubscribed $52.5M Series B for peripheral nerve stimulation technology, led by Amzak Health.

Nervonik

Nervonik Lumira Ventures

lumiraventures.comAPR 27, 2026

APR 27, 2026

3 team changes· APR 2026Show all

Team Change

Isabelle Harris was promoted to Associate, focusing on sourcing and evaluating new biotech and medtech investment opportunities.

Isabelle Harris promoted to Associate

Lumira Ventures

lumiraventures.comAPR 20, 2026

APR 20, 2026

Team Change

Peter van der Velden transitioned to the role of Executive Chairman as part of the firm's leadership succession plan.

Peter van der Velden transitions to Executive Chairman

Lumira Ventures

lumiraventures.comAPR 20, 2026

APR 20, 2026

Team Change

Co-founder Gerry Brunk was named Managing Partner in conjunction with the first closing of Fund V.

Gerry Brunk named Managing Partner

Lumira Ventures

lumiraventures.comAPR 20, 2026

APR 20, 2026

Page 1 of 2